- Home
- APDN
as 12-18-2024 2:31pm EST
Applied DNA Sciences Inc is a biotechnology company developing and commercializing technologies to produce and detect deoxyribonucleic acid (DNA) nd ribonucleic acid (RNA). The company operates in three business segments- Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. It generates majority of its revenue from the MDx Testing Services which is involved in performing and developing clinical molecular diagnostic and genetic tests and clinical laboratory testing services. The company provides its products and services under the brand of Applied DNA Sciences, SigNature molecular tags, SigNature T molecular tags, fiberTyping, SigNify and others.
| Founded: | 1983 | Country: | United States |
| Employees: | N/A | City: | STONY BROOK |
| Market Cap: | 8.9M | IPO Year: | N/A |
| Target Price: | $1.50 | AVG Volume (30 days): | 8.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.87 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.12 - $14.40 | Next Earning Date: | 02-06-2025 |
| Revenue: | $3,398,049 | Revenue Growth: | -78.96% |
| Revenue Growth (this year): | -73.17% | Revenue Growth (next year): | 48.01% |
Latest Applied DNA Sciences Inc. News
APDN Breaking Stock News: Dive into APDN Ticker-Specific Updates for Smart Investing
ACCESSWIRE
6 hours ago
Applied DNA Customer ÚHKT Initiates Phase I Clinical Trial for Rapidly Manufacturable CAR T-Cell Therapy Produced from Linea DNA
Zacks
a day ago
Applied DNA Sciences (APDN) Reports Q4 Loss, Tops Revenue Estimates
Associated Press Finance
a day ago
Applied DNA Sciences: Fiscal Q4 Earnings Snapshot
ACCESSWIRE
a day ago
Applied DNA Announces Fourth Quarter and Fiscal Year 2024 Financial Results, Announces Strategic Restructuring to Prioritize the Manufacture of Critical Starting Materials for Genetic Medicines
ACCESSWIRE
2 days ago
Applied DNA to Report Fourth Quarter and Fiscal Year 2024 Financial Results After Market Close on December 17, 2024; Sets Webcast and Conference Call for January 9, 2025, to Coincide with Update on GMP Manufacturing Facility Build-out
MT Newswires
a month ago
APDN Files for Resale of 41.6 Million Shares by Selling Stockholders
ACCESSWIRE
2 months ago
Applied DNA Announces Pricing of $6.5 Million Registered Direct Offering and Concurrent Private Placement
ACCESSWIRE
2 months ago
Applied DNA to Participate in the 2024 Maxim Healthcare Virtual Summit on Wednesday, October 16
Compare APDN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "APDN Applied DNA Sciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.